MedTrace Logo

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

NCT00747175 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes

Conditions

Interventions

DRUG

AZD1656

Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment

DRUG

AZD1656

Dose titration of oral suspension to a tolerable dose, 1 month treatment

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, Phd, Prof · AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden

  • Marcus Hompesch, MD · Profil Institute for Clinical Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00747175 on ClinicalTrials.gov